Galderma Operating Cycle from 2010 to 2026

GALD Stock   145.90  0.20  0.14%   
Galderma Group Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 208.41 in 2026. During the period from 2010 to 2026, Galderma Group Operating Cycle regression line of quarterly data had mean square error of  92.50 and geometric mean of  198.36. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
210.87
Current Value
208.41
Quarterly Volatility
9.37252787
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Galderma Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galderma Group's main balance sheet or income statement drivers, such as Tax Provision of 54.1 M, Interest Income of 350.3 M or Depreciation And Amortization of 265.5 M, as well as many indicators such as Price To Sales Ratio of 3.27, Dividend Yield of 0.0 or PTB Ratio of 3.29. Galderma financial statements analysis is a perfect complement when working with Galderma Group Valuation or Volatility modules.
  
This module can also supplement various Galderma Group Technical models . Check out the analysis of Galderma Group Correlation against competitors.
The evolution of Operating Cycle for Galderma Group N provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Galderma Group compares to historical norms and industry peers.

Latest Galderma Group's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Galderma Group N over the last few years. It is Galderma Group's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galderma Group's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Pretty Stable
   Operating Cycle   
       Timeline  

Galderma Operating Cycle Regression Statistics

Arithmetic Mean198.58
Geometric Mean198.36
Coefficient Of Variation4.72
Mean Deviation5.24
Median199.89
Standard Deviation9.37
Sample Variance87.84
Range41.6221
R-Value(0.11)
Mean Square Error92.50
R-Squared0.01
Significance0.67
Slope(0.21)
Total Sum of Squares1,406

Galderma Operating Cycle History

2026 208.41
2025 210.87
2024 183.37
2023 169.25
2022 205.32

About Galderma Group Financial Statements

Galderma Group investors use historical fundamental indicators, such as Galderma Group's Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Galderma Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 210.87  208.41 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Galderma Stock Analysis

When running Galderma Group's price analysis, check to measure Galderma Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galderma Group is operating at the current time. Most of Galderma Group's value examination focuses on studying past and present price action to predict the probability of Galderma Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galderma Group's price. Additionally, you may evaluate how the addition of Galderma Group to your portfolios can decrease your overall portfolio volatility.